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Introduction: In this study, we investigated the difference in the
surgical results of non-small cell lung cancer according to the
method of initial detection.
Methods: We reviewed the medical records of 796 patients who
underwent pulmonary resection for non-small cell lung cancer
between 1994 and 2005. The subjects consisted of 171 patients
whose cancer was detected by a medical checkup or mass health
screening (group I), 316 patients who were under evaluation for
other diseases or with symptoms related to other diseases (group II),
and 309 patients with lung cancer–related symptoms (group III). The
mean ages of the three groups were 63.2, 69.7, and 68.2 years old,
respectively, with group I being significantly younger than the other
groups. The proportion of women in the symptomatic group was
significantly lower than that of men.
Results: Pathologic stage I lung cancer was found in 112 (65.5%),
209 (65.2%), and 110 (35.6%) patients in groups I, II, and III,
respectively. In comparison with stage II–IV cancer, stage I cancer
was diagnosed more frequently in group I. According to the histo-
logic type, adenocarcinoma was found in 132 patients (77.2%) in
group I. However, squamous cell carcinoma was detected in only 27
patients (15.8%) in group I. The overall 5-year survival rates were
71.9%, 60.2%, and 48.0% in groups I, II, and III, respectively.
Groups I and II had significantly better prognoses than group III.
Conclusion: Groups I and II had favorable prognoses, and the
presence of symptoms related to lung cancer was a significantly
unfavorable prognostic factor independent of all other factors.
Key Words: Lung cancer, Mass health screening, Initial detection,
Pulmonary resection, Surgical outcome.
(J Thorac Oncol. 2007;2: 907–911)
Lung cancer is still the leading cause of cancer mortality inboth men and women in many industrialized countries.1,2
In the United States and Western European countries, the
peak of the lung cancer epidemic was reached in the 1990s,
and the incidence rate is now decreasing.2 Intensive aware-
ness campaigns to discourage smoking have greatly contrib-
uted to the prevention of lung cancer in Western countries as
primary prophylaxis.3 Conversely, mass health screening by
chest radiographs as secondary prevention has also been
abandoned in several countries except for Japan.4,5 Screening
chest radiography is not considered effective because it is not
accurate enough, and false-positive findings frequently result
in additional and unnecessary medical tests, and thus unnec-
essary expense, and patient anxiety and stress.6–8 At present,
the evidence is not sufficient to support chest radiographic
screening for lung cancer in a randomized, controlled trial.9
However, primary care physicians throughout the world still
use chest radiography for screening patients who are sus-
pected of having respiratory and cardiovascular disease.
Lung cancer remains a considerable public health prob-
lem, and reducing the mortality of lung cancer remains an
important issue. Complete surgical resection is considered the
first-line treatment for individuals with stage I–II non-small
cell lung cancer (NSCLC). The cure rates following surgery,
even for stage I NSCLC, are only approximately 70%.10
However, the majority of NSCLC patients present with ad-
vanced inoperable disease, and patients diagnosed at ad-
vanced stages tend to have an extremely poor prognosis.10,11
The difficulty of achieving curative treatment for patients
with advanced stage disease suggests that early intervention
in the preclinical or early stage might decrease the cancer-
specific mortality. Advanced-stage NSCLC is also associated
with many symptoms such as dyspnea, cough, fatigue, an-
orexia/cachexia, and pain.12 The detection of lung cancer
before the appearance of symptoms might result in a more
favorable postoperative prognosis. In the present study, we
reviewed the clinical records of lung cancer patients who
underwent surgical resection to evaluate the clinical features
and prognosis according to the method of initial detection.
PATIENTS AND METHODS
In this study, we examined the clinical and pathologic
features according to the method of initial detection in 796
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consecutive patients with primary NSCLC who underwent
surgical resection in our department between 1994 and 2005.
Any patients who underwent an exploratory thoracotomy
were excluded from this study. The patients’ records were
retrieved, and the clinical data, preoperative examination
results, details of surgical operation, histopathologic findings,
and TNM stages of all patients were also reviewed. The
preoperative assessments included chest radiography, com-
puted tomography (CT) of the chest and upper abdomen,
magnetic resonance imaging of the brain, bronchoscopy, and
bone scintigraphy. All resected specimens including primary
tumor and systematically resected hilar and mediastinal lymph
nodes were examined for tumor histology and the extent of
lymph node metastases. The histopathologic findings were clas-
sified according to the World Health Organization criteria and
the UICC TNM staging system was employed.13,14
To evaluate the prognostic differences among the meth-
ods of detection of NSCLC, the patients were classified into
three groups: patients whose cancer was detected by a med-
ical checkup or mass health screening (health check group;
group I), patients under evaluation for other diseases or with
symptoms related to other diseases (other diseases group;
group II), and patients with lung cancer–related symptoms
(symptomatic group; group III). In group II, the disease was
currently being treated or had been treated either before or
after surgery for lung cancer. Follow-up information was
obtained from all patients through office visits or telephone
interviews with the patient, a relative, or the primary physi-
cian. The mean observation time of each group was 3.5 years
(range, 2–120 months). The mean observation time of groups
I, II, and III was 3.9 years (range, 2–120 months), 3.2 years
(range, 4–120 months), and 3.9 years (range, 2–120 months),
respectively.
Categorical variables were compared by Fisher’s exact
test for proportion. The survival curve was calculated by the
Kaplan-Meier method and compared by using the log-rank
test for univariate analysis. Postoperative deaths were in-
cluded in the survival estimates. Prognostic factors were
analyzed by a multivariate analysis using Cox’s proportional
hazard model after adjusting for potential confounding fac-
tors. The differences were considered to be significant, if p 
0.05. The Statview V software program (Abacus Concept,
Berkeley, CA) was used for all statistical analyses.
RESULTS
The subjects consisted of 171 patients who had under-
gone a medical checkup or mass health screening (group I),
316 patients under evaluation for other diseases or with
symptoms related to the diseases (group II), and 309 patients
with lung cancer–related symptoms (group III) (Table 1). The
mean ages of the three groups were 63.2, 69.7, and 68.2 years
old, respectively, and group I was significantly younger than
the other groups. Among group I, 168 patients were detected
by chest radiography, whereas three patients were identified
by CT as a screening. There were 107 (62.6%), 204 (64.6%),
and 234 (75.7%) men in groups I, II, and III, respectively.
There were 64 (37.4%), 112 (35.4%), and 75 (24.3%) women
in groups I, II, and III, respectively. The proportion of women
with symptoms was significantly lower than that of men. As
regards T factor, T1 lung cancer was detected in 95 (55.6%),
177 (56%), and 78 (25.2%) in groups I, II, and III, respec-
tively. The proportion of T1 cases in group III was signifi-
cantly lower than that in other groups (p  0.01). In terms of
N factor, the proportion of N0 cases in group III was signif-
icantly lower than that in other groups (p  0.05). Pathologic
stage I lung cancer was found in 112 (65.5%), 209 (65.2%),
and 110 (35.6%) in groups I, II, and III, respectively. The
stage I patients were diagnosed more frequently through
either medical health checkups or evaluations for other dis-
eases before the development of symptoms. According to the
histologic type, adenocarcinoma was found in 132 (77.2%)
and 222 (70.2%) patients in groups I and II, respectively.
However, adenocarcinoma was detected in 132 (42.7%) pa-
tients in group III.
Among the stage I patients, the 5-year survival rates
were 83.3%, 69.9%, and 66.3% in groups I, II, and III,
TABLE 1. Characteristics of Non-small Cell Lung Cancer
Patients According to Method of Initial Detection
No. (%) of Patients
Group I
(n  171)
Group II
(n  316)
Group III
(n  309)
Characteristics
Male 107 (62.6) 204 (64.6) 234 (75.7)
Female 64 (37.4) 112 (35.4) 75 (24.3)a
Histology
Adenocarcinoma 132 (77.2) 222 (70.2) 132 (42.7)b
Squamous cell carcinoma 27 (15.8) 66 (20.9) 136 (44.0)
Other 12 (7.0) 28 (8.9) 41 (13.2)
T factor
T1 95 (55.6) 177 (56.0) 78 (25.2)c
T2 51 (29.8) 94 (29.7) 121 (39.2)
T3 11 (6.4) 16 (5.1) 64 (20.7)
T4 14 (8.2) 28 (8.9) 46 (14.9)
N factor
N0 123 (71.9) 233 (73.7) 154 (49.8)d
N1 15 (8.8) 20 (6.3) 58 (18.8)
N2 30 (17.5) 58 (18.4) 88 (28.5)
N3 3 (1.7) 4 (1.3) 9 (2.9)
Pathologic stage
IA 80 (46.8) 149 (46.2) 51 (16.5)e
IB 32 (18.7) 60 (19.0) 59 (19.1)
II 15 (8.8) 24 (7.6) 63 (20.4)
III 40 (23.4) 69 (21.8) 117 (37.9)
IV 4 (2.3) 14 (4.4) 19 (6.1)
a The proportion of patients with symptoms was significantly lower in women than
in men (p  0.05).
b The incidence of adenocarcinoma in group III was significantly lower than that in
other groups (p  0.01).
c The proportion of T1 cases in group III was significantly lower than that in other
groups (p  0.01).
d The proportion of N0 cases in group III was significantly lower than that in other
groups (p  0.05).
e Stage IA cancer was diagnosed less frequently in group III than that in other
groups (p  0.05).
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respectively (Figure 1). The overall 5-year survival rates were
71.9%, 60.2%, and 48.0% in groups I, II, and III, respectively
(Figure 2). We performed a multivariate analysis using other
variables such as gender, age, pathologic stage, T factor, and
N factor as significant prognostic factors. In terms of overall
survival, detection by a medical checkup or mass health
screening was found to be a significant prognostic factor
independent of the other factors (p  0.003) (Table 2). When
the patients who died of other diseases were excluded, the
5-year survival rates of patients with stage I disease were
89.4%, 88.7%, and 80.7% in groups I, II, and III, respectively
(Figure 3). The 5-year survival rates in cancer-related deaths
were 76.3%, 75.6%, and 58.2% in groups I, II, and III,
respectively (Figure 4). Groups I and II had significantly
more favorable prognoses than group III (Table 3).
FIGURE 1. Overall survival curves of patients with patho-
logic stage I disease. Among the stage I patients, the 5-year
survival rates were 83.3%, 69.9%, and 66.3% in groups I, II,
and III, respectively. Group I tended to have more favorable
prognoses than groups II (p  0.11) and III (p  0.08).
FIGURE 2. Overall survival curves of patients with lung can-
cer. The 5-year survival rates were 71.9%, 60.2%, and 48.0%
in groups I, II, and III, respectively. Group I had significantly
more favorable prognoses than group III (p  0.001).
FIGURE 3. Cancer-specific survival of patients with stage I
disease. With the exception of death due to unrelated dis-
ease, the 5-year survival rates 89.4%, 88.7%, and 80.7% in
groups I, II, and III, respectively. Groups I and II tended to
have favorable prognoses than group III (p  0.07).
FIGURE 4. Cancer-specific survival of patients with lung can-
cer. With the exception of death due to unrelated disease, the
5-year survival rates were 76.3%, 75.6%, and 58.2% in groups
I, II, and III, respectively. Groups I and II had significantly more
favorable prognoses than group III (p  0.001).
TABLE 2. Multivariate Cox Proportional Hazard Analysis of
the Overall Survival
Factors RR 95% CI p
Women vs. men 0.734 0.541–0.997 0.047
Tumor size (T1 vs. T2–4) 0.412 0.303–0.560 0.001
Nodal status (N0 vs. N1–3) 0.494 0.383–0.636 0.001
Histology (adenocarcinoma vs. other) 0.943 0.761–1.289 0.990
Age (75 yr vs. 75 yr) 0.746 0.563–0.990 0.043
Method of initial detection
(group I vs. groups II and III)
0.588 0.415–0.834 0.003
RR, relative risk; CI, confidence interval.
TABLE 3. Multivariate Cox Proportional Hazard Analysis of
the Cancer-Specific Survival
Factors RR 95% CI p
Women vs. men 0.899 0.629–1.285 0.449
Tumor size (T1 vs. T2–4) 0.357 0.238–0.536 0.001
Nodal status (N0 vs. N1–3) 0.336 0.243–0.464 0.001
Histology (adenocarcinoma vs. other) 1.291 0.926–1.801 0.132
Age (75 yr vs. 75 yr) 0.967 0.663–1.412 0.043
Method of initial detection
(group III vs. groups I and II)
1.416 1.027–1.953 0.034
RR, relative risk; CI, confidence interval.
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DISCUSSION
Many researchers have investigated the value of screen-
ing for lung cancer, which would theoretically allow earlier
detection and more effective treatment.4–7 However, there is
no significant evidence that indicates that mass screening for
lung cancer with chest radiography has a prognostic benefit,
and as a result, no major organization currently recommends
chest radiography as a screening method for lung cancer
except for Japan. It has been reported that chest radiography
is not sufficiently sensitive to identify early lung cancer and
that overdiagnosis often leads to unnecessary invasive diag-
nostic procedures and treatments.8 However, four different
case-control studies in Japan demonstrated that lung cancer
screening by combination of chest radiography with sputum
cytology resulted in a reduction in lung cancer mortality.15–18
Low-dose chest CT scanning (LDCCT scanning) is
reported to be useful for detecting early peripheral NSCLC.19
The Early Lung Cancer Action Project demonstrated the
prevalence rate of lung cancer as detected by CT to be 2.7%
among the 1000 current or ex-smokers older than 60 years of
age, and 85% of these demonstrated stage I disease.20 Sobue
et al.21 reported the 5-year survival rate for CT screening–
detected lung cancer to be approximately 76.2%. These
findings suggest that LDCCT screening therefore has the
potential to improve the survival of lung cancer patients.
Because the incidence of peripheral adenocarcinoma has
increased significantly worldwide, especially exceeding a
50% increase in many areas of Europe,22 CT is considered to
positively contribute to the detection of this peripheral lung
cancer. However, the role of LDCCT in screening for lung
cancer remains controversial because a high false-positive
rate associated with LDCCT results in unnecessary interven-
tion for benign disease while also increasing patient anxi-
ety.23 LDCCT screening can detect very small lung abnor-
malities; however, the false-positive rate of LDCCT has been
reported to range from 20% to 50%, thus resulting in over-
diagnosis and overtreatment.23–26
There was a significantly lower percentage of women
than men in the symptomatic group in the present study.
Cancer was detected in two thirds of all women either during
a medical check for some diseases or during a mass screen-
ing. According to the histologic type, disease in 132 (27.1%)
of 486 adenocarcinoma patients was found by symptoms,
although squamous cell carcinoma was detected by symp-
toms in 136 (59.4%) of 229 patients. Squamous cell carci-
noma often develops in the central airway, which might be
difficult to detect by chest radiography performed during
regular health checkups until symptoms develop.27,28
The stage IA disease was diagnosed less frequently in
the symptomatic group than in the other groups. The health
check group and the other diseases group had significantly
better prognoses than the symptomatic group with regard to
the overall 5-year survival rate. Even in stage II–IV disease
cases, the prognoses of the health check group were better
than those of symptomatic group. When deaths from other
diseases were excluded, the 5-year survival rates in the other
diseases group were almost the same as those for the health
check group and better than those for the symptomatic group.
This suggests that detection by chance during evaluations for
other diseases also contributed to a better prognosis after
surgery. Furthermore, multivariate analysis revealed that lung
cancer detected by health checks was an independent prog-
nostic factor, with the overall survival rate as the endpoint.
The international Early Lung Cancer Action Program
investigators reported that annual spiral CT screening de-
tected curable lung cancer.29 These advances in imaging
technology have made it possible to detect most cancers
much earlier than had the patients presented with clinical
signs or symptoms. However, there has been much discussion
about lead-time bias in radiographic screening for lung can-
cer.30,31 The difference in survival between patients with
different stages could be related to lead-time bias. The New
York Early Lung Cancer Action Project regimen of screening
also revealed that annual CT screening for lung cancer
resulted in identification of a high proportion of patients with
early-stage disease.32 If the lung cancer is curable by a
surgical resection in the early stage, then the effect of lead-
time bias may be small. However, an overdiagnosis bias
should be considered in such cases because new imaging
technologies can detect very small lung nodules. Overdiag-
nosed cancers would not be symptomatic because the disease
is indolent or, death from another cause, for potentially fatal
disease, may often precede the theoretical date of the symp-
tomatic detection.33
Although it is not clear whether the early detection of
lung cancer through mass screening and annual checkups
results in a net benefit to the public health, there was a
significantly higher proportion of patients with lung cancer
detected by health checkups in the early stages; therefore, lung
cancer screening is considered to contribute to some extent to the
early detection of lung cancer. We conclude that the health
check and other diseases groups both had better prognoses, and
the presence of symptoms related to lung cancer was a signifi-
cant prognostic factor independent of all other factors.
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